Updated:
Tentamus Group
Jochen P. Zoller co-founded Tentamus Group in 2011. The Berlin-headquartered laboratory network has deployed over $1 billion in acquisitions worldwide.
Tentamus Group
Jochen P. Zoller launched Tentamus Group in Berlin in 2011 with a focused thesis: acquire and integrate founder-led testing, inspection, and certification labs across Europe, then scale into the Americas and Asia. The group now counts over 4,000 professionals in a network of roughly 100 laboratories operating in more than 20 countries. Tentamus Labs provide analytical testing across the full lifecycle — from raw-material screening through batch release — for the food, pharmaceuticals, and agrochemicals industries. The firm deploys capital almost exclusively through direct acquisitions, targeting laboratories with strong local franchises it can retain and integrate. Tentamus operates across three broad verticals: food safety and authenticity testing, pharmaceutical quality control and stability studies, and agroscience services including residues and environmental fate. Known subsidiaries include bilacon GmbH (Berlin, food safety), QSI Quality Service International (Bremen, honey analysis), and LVA Labor für Veterinär- und Analytik (Karlsruhe, pharma). Geographic concentration remains deepest in Germany, with growing footprints in the United Kingdom, the United States, China, Japan, and Mexico. Tentamus has not publicly disclosed total assets under management or standalone revenue, but the group has deployed more than $1 billion in acquisitions since founding, per the firm's official communications. The holding company is backed by private equity investor Afinum, which took a minority stake in 2016 to accelerate the buy-and-build strategy. Tentamus itself maintains no fund vehicles outside the parent entity; capital is held at the group level and deployed for direct acquisitions. A structural differentiator is Tentamus' combination of high-volume commodity testing with high-complexity, regulated services. Unlike most private equity-backed lab platforms that consolidate based on geography or standalone revenue, Tentamus layers a proprietary quality management system and LIMS software stack across all its subsidiaries. This creates interoperability that regulatory clients — particularly global pharma sponsors and European food retailers — require from a single supplier, a capability few independent lab consolidators can replicate.
General information
Firm type
Asset Manager
Year founded
2011
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Berlin
Corporate office
Berlin, Germany
Principals
Jochen P. Zoller
CEO
Sector focus
Frequently asked questions
Who runs investment decisions at Tentamus Group?
Investment and acquisition decisions are led by CEO and co-founder Jochen P. Zoller in coordination with the group's board. The firm is backed by minority investor Afinum, a German private equity manager, which provides strategic guidance and acquisition financing. No independent investment committee structure or external allocator influence is publicly disclosed.
How does Tentamus Group source acquisition targets?
Tentamus sources laboratories primarily through a proprietary deal-sourcing network in European specialty testing, working through industry conferences, regional accounting firms focused on founder transitions, and referrals within its existing subsidiary management teams. The group targets founder-operated labs where principals want partial liquidity and continued operating involvement. The buy-and-build pipeline is concentrated in regulated food safety, pharmaceutical, and agroscience verticals.
Is Tentamus structured as a family office, a private equity firm, or an operating company?
Tentamus operates as a holding company that wholly owns and integrates specialty laboratory businesses. While it deploys acquisition capital similar to a buy-and-build private equity strategy, it has no external fund structure and reports as an operating group. The firm is not known to represent family office wealth; its primary capital source is minority sponsor Afinum plus internally generated cash flows.
Does Tentamus participate in fund commitments or club deals with other investors?
No public record indicates Tentamus participates in third-party fund commitments or club deal structures. The group buys laboratories on a proprietary basis, typically negotiating directly with founder-sellers and holding the assets indefinitely. No co-investment vehicle open to external family offices or institutions is known to exist.
Which regions does Tentamus currently prioritize for expansion?
Tentamus has stated publicly that it prioritizes deeper coverage in the United States, Asia-Pacific (particularly China and Japan), and Latin America for its food and pharma testing services. The group has established beachhead acquisitions in the US, UK, Mexico, and multiple Asian markets, and continues to seek bolt-on laboratories in regulated OECD markets where harmonized GMP and ISO standards support its central quality-management integration model.
What is Tentamus' relationship with Afinum, and does it affect governance?
Afinum, a German mid-market private equity firm, acquired a minority stake in Tentamus Group in 2016 to provide growth capital for the laboratory acquisition strategy. Afinum is represented on the group's board but does not manage day-to-day operations. The structure preserves the original founder-management team's operating control while giving Afinum governance rights typical of a minority growth investment.
Does Tentamus maintain any separate philanthropic or impact investing structures?
No separate philanthropic foundation or impact investing vehicle is publicly associated with Tentamus Group or its founders. The firm's social and environmental activities appear limited to the operational scope of its laboratories, such as food authenticity testing that supports public health and consumer safety.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: